QURE
uniQure NV
NASDAQ · Healthcare · Biotechnology · NL
$44.00
−0.20%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$44.20
From 52W high−37.67%
Volume2.08M
Market cap$3.05B
P/E (TTM)—
P/S (TTM)163.5x
Div yield—
Key dataSep 18, 2026
Open
$44.20
From 52W high
−37.67%
Volume
2.08M
Market cap
$3.05B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−12.7x
P/E (TTM)
—
RSI (14)
44.5
MomentumView details →
1D Return
−0.20%
YTD Return
+83.35%
SummaryUpdated Jun 1, 2026
uniQure N.V. (NASDAQ:QURE) is a Dutch gene therapy company founded in 1998 and headquartered in Amsterdam, the Netherlands. The company went public on NASDAQ in February 2014. uniQure focuses on developing gene therapies for patients suffering from genetic and other devastating diseases, with a particular emphasis on rare neurological conditions and inherited disorders. The company has evolved from its early research phases to become a clinical-stage biotechnology firm with multiple programs advancing through various stages of human trials.
Similar companies
Latest newsMore news →
uniQure submitted a Biologics License Application to the U.S. FDA for its Huntington's disease gene therapy after the FDA reversed its earlier position on the drug.18d agouniQure reported a quarterly loss of $1.22 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.81 per share and compared to a loss of $0.69 per share a year ago.53d agouniQure N.V. signed an underwriting agreement for an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, with underwriters fully exercising an option for additional shares, expected to close on June 25, 2026.89d ago